CD274 and cancer: G207 is an oHSV-1 with a deletion in the major neurovirulence gene ICP34.5 and a mutation in the ICP6 ribonucleotide reductase gene, enabling it to replicate selectively in and kill cancer cells.3 21 Clinical trials using G207 have demonstrated virus potency and safety in patients with cancer31–33 that can be further potentiated by encoding biologicals for expression within tumor cells.34 We engineered oHSV-1 to express PD-L1 scFv, PD-L1 NB and control BiTE (see Materials and Methods; figure 5A).